Loading…
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $41M | $-149M | $-160M | $-166M | -586.6% | 25.4% | - |
| 2024 | $32M | $-229M | $-237M | $-219M | -176.6% | -58.6% | - |
| 2023 | $78M | $-163M | $-153M | $-137M | -43.9% | 296.3% | - |
| 2022 | $20M | $-220M | $-220M | $-181M | -61.1% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 19.71 | 78.12 | 32.31 | 40.52 |
| Operating Expense | 245.66 | 247.30 | 271.23 | 139.86 |
| Operating Income | -225.95 | -169.18 | -238.92 | -99.34 |
| EBITDA | -219.61 | -163.12 | -229.09 | -148.61 |
| EBIT | -225.95 | -169.18 | -234.90 | -153.89 |
| Pretax Income | -220.43 | -153.22 | -237.09 | -160.06 |
| Net Income | -220.43 | -153.22 | -237.09 | -160.06 |
| Net Income Common Stockholders | -220.43 | -153.22 | -237.09 | -160.06 |
| Total Expenses | 245.66 | 247.30 | 271.23 | 139.86 |
| Interest Expense | 0 | 0 | 2.19 | 6.17 |
| Interest Income | 5.52 | 17.57 | 16.25 | 8.31 |
| Research And Development | 174.96 | 177.65 | 199.25 | 89.95 |
| Selling General And Administration | 70.70 | 69.65 | 71.99 | 49.90 |
| Normalized EBITDA | -219.61 | -163.12 | -216.86 | -87.94 |
| Normalized Income | -220.43 | -153.22 | -224.86 | -99.39 |
| Basic EPS | -3.21 | -2.02 | -2.88 | 0 |
| Diluted EPS | -3.21 | -2.02 | -2.88 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0 | 0 | -12.23 | -60.67 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | -12.23 | -60.67 |
| Net Income From Continuing Operation Net Minority Interest | -220.43 | -153.22 | -237.09 | -160.06 |
| Reconciled Depreciation | 6.34 | 6.06 | 5.81 | 5.28 |
| Net Interest Income | 5.52 | 17.57 | 14.06 | 2.14 |
| Net Income From Continuing And Discontinued Operation | -220.43 | -153.22 | -237.09 | -160.06 |
| Total Operating Income As Reported | -225.95 | -169.18 | -251.15 | -160.01 |
| Diluted Average Shares | 68.66 | 75.97 | 82.34 | 0 |
| Basic Average Shares | 68.66 | 75.97 | 82.34 | 0 |
| Diluted NI Availto Com Stockholders | -220.43 | -153.22 | -237.09 | -160.06 |
| Net Income Including Noncontrolling Interests | -220.43 | -153.22 | -237.09 | -160.06 |
| Net Income Continuous Operations | -220.43 | -153.22 | -237.09 | -160.06 |
| Other Income Expense | 1.29 | -1.60 | -12.23 | -62.86 |
| Other Non Operating Income Expenses | 1.29 | -1.60 | 0 | -2.19 |
| Special Income Charges | 0 | 0 | -12.23 | -60.67 |
| Restructuring And Mergern Acquisition | 0 | 0 | 12.23 | 60.67 |
| Net Non Operating Interest Income Expense | 5.52 | 17.57 | 14.06 | 2.14 |
| Interest Expense Non Operating | 0 | 0 | 2.19 | 6.17 |
| Interest Income Non Operating | 5.52 | 17.57 | 16.25 | 8.31 |
| General And Administrative Expense | 70.70 | 69.65 | 71.99 | 49.90 |
| Other Gand A | 70.70 | 42.73 | 38.45 | 30.66 |
| Salaries And Wages | 34.19 | 26.93 | 33.54 | 19.24 |
| Operating Revenue | 19.71 | 78.12 | 32.31 | 40.52 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Editas Medicine, Inc.this co. | EDIT | $276M | - | 10.11 | -586.6% | -1.57 |
| Protara Therapeutics, Inc. | TARA | $285M | - | 1.41 | -29.2% | -1.99 |
| LENZ Therapeutics, Inc. | LENZ | $284M | - | 1.00 | -28.9% | 0.09 |
| Simulations Plus, Inc. | SLP | $283M | - | 2.11 | -51.9% | 17.29 |
| RxSight, Inc. | RXST | $282M | - |
| 1.02 |
| -14.1% |
| -1.42 |
| Foghorn Therapeutics Inc. | FHTX | $279M | - | -2.49 | 68.5% | -2.05 |
| Accendra Health, Inc. | ACH | $267M | - | -0.58 | 238.8% | 5.96 |
| Eledon Pharmaceuticals, Inc. | ELDN | $266M | - | 1.84 | -56.3% | - |
| TriSalus Life Sciences, Inc. | TLSI | $262M | - | -6.29 | 115.8% | -10.46 |
| Peer Median | - | - | 1.01 | -21.5% | -1.42 | |